Publication Cover
Neurological Research
A Journal of Progress in Neurosurgery, Neurology and Neurosciences
Volume 43, 2021 - Issue 9
328
Views
3
CrossRef citations to date
0
Altmetric
Original Research Paper

Expression levels of IL-17/IL-23 cytokine-targeting microRNAs 20, 21, 26, 155, and Let-7 in patients with relapsing-remitting multiple sclerosis

&
Pages 778-783 | Received 22 Jul 2020, Accepted 23 May 2021, Published online: 16 Jun 2021

References

  • Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. HandbClinNeurol. 2014 Oct;122:513–562.
  • Ozakbas S, Yigit P, Cinar BP, et al. The Turkish validation of the BriefInternational Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. BMC Neurol. 2017 Dec;17:208.
  • Teymoori-Rada M, Mozhgani S-H, Zarei-Ghobadi M, et al. Integrational analysis of miRNAs data sets as a plausible missing linkerbetween Epstein-Barr virus and vitamin D in relapsing remitting MS patients. Gene. 2019 Dec;689:1–10.
  • Salvi V, Gianello V, Tiberio L, et al. Cytokine targeting by miRNAs inAutoimmune diseases. Front Immunol. 2019 Jan;15(10):1–10.
  • Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007 Apr;25(1):821–852.
  • Sutton CE, Mielke LA, Mills KH. IL-17-producing gammadeltaTcells and innate lymphoid cells. Eur J Immunol. 2012 Sep;42:2221–2231.
  • Amatya N, Garg AV, Gaffen SL. IL-17 signaling: the yin and the yang. TrendsImmunol. 2017 Dec;38:310–322.
  • Chen JQ, Papp G, Szodoray P, et al. The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev. 2016 Sep;15(12):1171–1180.
  • Zhang R, Tian A, Wang J, et al. miR26a modulates Th17/Treg balance in the EAE model of multiple sclerosis by targeting IL6. Neuromol Med. 2015 Nov;17:24–34
  • Mameli G, Arru G, Caggiu E, et al. Natalizumab therapy modulates miR-155, miR-26a and proinflammatorycytokine expression in MS patients. PLoSONE. 2016 Jun;11:e0157153.
  • Guan H, Fan D, Mrelashvili D, et al. MicroRNA let-7e is associated with the pathogenesis of experimentalautoimmune encephalomyelitis. Eur J Immunol. 2013 Jun;43:104–114.
  • Goldschmidt T, Antel J, König FB, et al. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology. 2009 Jun 2;72(22):1914–1921.
  • Tufekci KU, Mg O, Genc S, et al. MicroRNAs and multiple sclerosis. SAGE-Hindawi Access to Research. Autoimmune Dis. 2010 Oct 11;2011:807426.
  • Cox MB, Cairns MJ, Gandhi KS, et al. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One. 2010 Aug 11;5(8):e12132.
  • Keller A, Leidinger P, Lange J, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One. 2009 13;4(10):e7440.
  • Murugaiyan G, da Cunha AP, Ajay AK, et al. MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J Clin Invest. 2015 Feb 2;125(3):1069–1080.
  • Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiationand is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009 Oct;1012:1252–1259.
  • Fenoglio C, Cantoni C, De Riz M, et al. Expression and geneticanalysisofmiRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett. 2011 Oct;504:9–12.
  • Junker A, Krumbholz M, Eisele S, et al. MicroRNA profiling of multiplesclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009 Dec;132:3342–3352.
  • Ma X, Zhou J, Zhong Y, et al. ReviewExpression, regulation and function of MicroRNAs inMultiple Sclerosis. Int J Med Sci. 2014 June;11(8):810–818.
  • Mohammed EMA. Multiple Sclerosis and the Pathogenicity of Mir-155. Biomed J Sci Tech Res. 2018 Oct;9(4):7316-7319.
  • Waschbisch A, Atiya M, Linker RA, et al. Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis. PLoS ONE. 2011;6(9):e24604.
  • Moore CS, Rao VT, Durafourt BA, et al. miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol.2013 July;74(5):709–720.
  • Madhan Thamilarasan, Dirk Koczan, Michael Hecker, Brigitte Paap, Uwe K Zettl MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. Autoimmun Rev2012 Jan;11(3):179.
  • Paraboschi EM, Soldà G, Gemmati D, et al. Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci. 2011 Dec;12(12):8695–8712.
  • Honardoost MA, Kiani-Esfahani A, Ghaedi K, et al. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis. Gene. 2014 Jul;544(2):128–133.
  • Yang D, Wang WZ, Zhang XM, et al. MicroRNA expression aberration inchinese patients with relapsing remitting multiple sclerosis. J Mol Neurosci. 2014 Jan;52:131–137.
  • Gandhi R, Healy B, Gholipour T, et al. Circulating microRNAs as biomarkersfor disease staging in multiple sclerosis. Ann Neurol. 2013;73:729–740.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.